How you can do your part in the AI transformation of oncology
An interview with ESMO President Prof. Fabrice André underscores the importance for any medical oncologist of developing artificial intelligence literacy
Study presents an AI-guided approach to target cancer antigens
The innovative approach was successfully tested on NY-ESO-1 and promises to bypass some current challenges in the identification of T cell receptors for therapeutic use
Cancer Control Principles
AI is impacting cancer care, but also the environment
Research shows that widespread use of artificial intelligence tools is associated with high demand for energy, water and minerals
Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity
Diverse approaches are investigated in oncology that also include the use of artificial intelligence
ESMO awards its first fellowship to support digital and computational pathology
The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones
A toolkit to address disparities in digitally enabled oncology trials
An initiative fosters inclusive research by improving patient access and participation in cancer research
AI and remote monitoring are shaping a new patient journey in oncology
Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting
Artificial Intelligence
Will AI reduce or increase inequities in cancer care?
While the use of artificial intelligence systems is expanding in oncology, ethical issues including biases introduced in care delivery and uneven access to technology raise concerns about whether some patients may be left behind
Pan-cancer AI model shows to predict 30-day mortality in patients with advanced cancer
In a study, a machine learning approach outperformed cancer-specific models and revealed universal biomarkers to guide end-of-life care decisions
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.